To the full analysis
Buyback calculator for Century Therapeutics
Century Therapeutics stock: key metrics
IPSCCentury Therapeutics had an operating margin of −13.8% and a return on invested capital (ROIC) of −21.4% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | no data | no data | no data |
| 2022 | 100.0% | −2,574.2% | −2,518.4% |
| 2023 | 100.0% | −6,556.9% | −6,115.1% |
| 2024 | 100.0% | −2,096.5% | −1,920.9% |
| 2025 | 88.0% | −13.8% | −8.8% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2019 | 200.0% | −18.0% | −100.0% |
| 2020 | 50.3% | −42.6% | −50.2% |
| 2021 | −24.2% | −29.0% | −21.9% |
| 2022 | −43.2% | −89.9% | −26.9% |
| 2023 | −74.0% | −28.7% | −37.9% |
| 2024 | −78.4% | −38.4% | −35.8% |
| 2025 | −6.0% | −21.4% | −4.3% |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.